First Manhattan’s Zymeworks ZYME Stock Holding History

First Manhattan’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-410	Closed	-$14K	–	1485
2020 Q1	$14K	Buy	+410	New	+$16.8K	﹤0.01%	1080

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Manhattan's ZYME Position: Q2 2020 in Review

First Manhattan sold out of Zymeworks (ZYME) in Q2 2020, closing a stake of 410 shares — an estimated $14K sold.

First Manhattan first reported a position in ZYME in Q1 2020 and held it in 1 quarter. The position peaked at $14K in Q1 2020. 133 funds tracked by Wall St. Rank hold ZYME as of Q2 2020.

First Manhattan reported no remaining Zymeworks position as of Q2 2020 after selling out during the quarter.
First Manhattan sold 410 Zymeworks shares in Q2 2020, an estimated $14K.
First Manhattan first reported a position in Zymeworks in Q1 2020 and held it in 1 quarter.
First Manhattan's Zymeworks position peaked at $14K in Q1 2020.
133 funds tracked by Wall St. Rank held Zymeworks as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.